King CS - Search Results

1

Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry.

King CS, Freiheit E, Brown AW, Shlobin OA, Aryal S, Ahmad K, Khangoora V, Flaherty KR, Venuto D, Nathan SD. King CS, et al. Chest. 2021 Apr;159(4):1507-1516. doi: 10.1016/j.chest.2020.10.019. Epub 2020 Oct 16. Chest. 2021. PMID: 33075376 Free article.

2

Native lung complications in single-lung transplant recipients and the role of pneumonectomy.

King CS, Khandhar S, Burton N, Shlobin OA, Ahmad S, Lefrak E, Barnett SD, Nathan SD. King CS, et al. J Heart Lung Transplant. 2009 Aug;28(8):851-6. doi: 10.1016/j.healun.2009.04.023. J Heart Lung Transplant. 2009. PMID: 19632585

3

Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases.

King C, Nathan SD. King C, et al. Curr Opin Pulm Med. 2013 Sep;19(5):466-73. doi: 10.1097/MCP.0b013e328363f460. Curr Opin Pulm Med. 2013. PMID: 23912191 Review.

4

Management of right heart failure in the critically ill.

King C, May CW, Williams J, Shlobin OA. King C, et al. Crit Care Clin. 2014 Jul;30(3):475-98. doi: 10.1016/j.ccc.2014.03.003. Crit Care Clin. 2014. PMID: 24996606 Review.

5

Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

Nathan SD, King CS. Nathan SD, et al. Among authors: king cs. Drug Des Devel Ther. 2014 Jul 2;8:875-85. doi: 10.2147/DDDT.S64907. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25061279 Free PMC article. Review.

6

Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease.

Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan MJ, Ahmad S, Newton KM, Weir N, Shlobin OA, Nathan SD. Shin S, et al. Among authors: king cs. Respir Med. 2014 Nov;108(11):1626-32. doi: 10.1016/j.rmed.2014.08.009. Epub 2014 Sep 2. Respir Med. 2014. PMID: 25225149 Free article.

7

Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.

King CS, Nathan SD. King CS, et al. Curr Opin Pulm Med. 2015 Sep;21(5):479-89. doi: 10.1097/MCP.0000000000000190. Curr Opin Pulm Med. 2015. PMID: 26164298 Review.

8

Organ Donors: Making the Most of What Is Offered.

Nathan SD, King CS. Nathan SD, et al. Among authors: king cs. Chest. 2015 Aug;148(2):303-305. doi: 10.1378/chest.15-1269. Chest. 2015. PMID: 26238828 No abstract available.

9

Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis.

Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD. Shin S, et al. Among authors: king cs. Eur Respir J. 2016 May;47(5):1445-51. doi: 10.1183/13993003.01532-2015. Epub 2016 Feb 4. Eur Respir J. 2016. PMID: 26846836 Free article.

10

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.

King CS, Nathan SD. King CS, et al. Chest. 2016 Aug;150(2):273-5. doi: 10.1016/j.chest.2016.04.034. Epub 2016 Jun 9. Chest. 2016. PMID: 27292047 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters